| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 120 | 1.43 | Why? |
| Sarcoma | 2 | 2019 | 290 | 1.13 | Why? |
| Mucus | 1 | 2020 | 183 | 0.74 | Why? |
| Prostatic Neoplasms | 8 | 2018 | 1637 | 0.71 | Why? |
| Cell Differentiation | 2 | 2019 | 1338 | 0.55 | Why? |
| Pathology, Molecular | 1 | 2017 | 343 | 0.52 | Why? |
| PTEN Phosphohydrolase | 4 | 2018 | 70 | 0.42 | Why? |
| Precision Medicine | 2 | 2018 | 1477 | 0.41 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.40 | Why? |
| Cell Line, Tumor | 7 | 2019 | 3608 | 0.30 | Why? |
| Transcriptome | 1 | 2018 | 3466 | 0.29 | Why? |
| Urinary Bladder Neoplasms | 3 | 2018 | 614 | 0.27 | Why? |
| Antigens, Neoplasm | 2 | 2003 | 230 | 0.26 | Why? |
| Monocarboxylic Acid Transporters | 1 | 2002 | 10 | 0.25 | Why? |
| Avian Proteins | 1 | 2002 | 15 | 0.24 | Why? |
| Phenotype | 4 | 2018 | 4037 | 0.24 | Why? |
| Cytoplasmic Granules | 1 | 2002 | 53 | 0.24 | Why? |
| Viral Load | 4 | 2021 | 15850 | 0.23 | Why? |
| Gene Expression Profiling | 5 | 2018 | 3788 | 0.23 | Why? |
| Symporters | 1 | 2002 | 80 | 0.23 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.23 | Why? |
| Antigens, Surface | 1 | 2002 | 181 | 0.22 | Why? |
| DNA, Neoplasm | 3 | 2017 | 56 | 0.20 | Why? |
| Pulmonary Alveoli | 2 | 2021 | 867 | 0.20 | Why? |
| Tauopathies | 1 | 2019 | 14 | 0.20 | Why? |
| Neoplasm Metastasis | 3 | 2018 | 682 | 0.20 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.19 | Why? |
| Prostatectomy | 2 | 2018 | 485 | 0.19 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.19 | Why? |
| Heterografts | 1 | 2019 | 203 | 0.19 | Why? |
| Neuropathology | 1 | 2019 | 95 | 0.19 | Why? |
| Sterol Regulatory Element Binding Proteins | 1 | 2018 | 22 | 0.18 | Why? |
| Adenosylmethionine Decarboxylase | 1 | 2017 | 2 | 0.18 | Why? |
| Lipogenesis | 1 | 2018 | 49 | 0.18 | Why? |
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 11 | 0.18 | Why? |
| Blood Proteins | 1 | 2002 | 551 | 0.18 | Why? |
| F-Box Proteins | 1 | 2017 | 13 | 0.18 | Why? |
| Polyamines | 1 | 2017 | 44 | 0.18 | Why? |
| Taxoids | 1 | 2017 | 45 | 0.18 | Why? |
| Immunity, Mucosal | 1 | 2021 | 426 | 0.17 | Why? |
| beta Karyopherins | 1 | 2017 | 31 | 0.17 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2021 | 449 | 0.17 | Why? |
| Cadmium | 1 | 2018 | 105 | 0.17 | Why? |
| Neoplasm Grading | 1 | 2018 | 400 | 0.16 | Why? |
| Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 67 | 0.16 | Why? |
| Neutralization Tests | 2 | 2021 | 6698 | 0.16 | Why? |
| Neoplastic Cells, Circulating | 1 | 2017 | 68 | 0.16 | Why? |
| Amyloid | 1 | 2017 | 156 | 0.16 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.16 | Why? |
| Osteogenesis | 1 | 2017 | 95 | 0.16 | Why? |
| Tretinoin | 1 | 2017 | 99 | 0.16 | Why? |
| Multiprotein Complexes | 1 | 2017 | 182 | 0.16 | Why? |
| Antigens, CD | 1 | 2002 | 984 | 0.16 | Why? |
| Microfluidic Analytical Techniques | 1 | 2018 | 254 | 0.16 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2018 | 242 | 0.15 | Why? |
| Tumor Suppressor Proteins | 1 | 2017 | 165 | 0.15 | Why? |
| Receptors, Androgen | 1 | 2018 | 212 | 0.15 | Why? |
| Post-Exposure Prophylaxis | 1 | 2020 | 472 | 0.15 | Why? |
| Amyloidosis | 1 | 2017 | 178 | 0.14 | Why? |
| Interleukin-1beta | 1 | 2020 | 992 | 0.14 | Why? |
| Carcinogenesis | 1 | 2017 | 236 | 0.14 | Why? |
| New York City | 7 | 2021 | 7432 | 0.14 | Why? |
| Autopsy | 3 | 2021 | 3495 | 0.14 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2017 | 385 | 0.14 | Why? |
| MicroRNAs | 2 | 2018 | 1787 | 0.14 | Why? |
| Interleukin-8 | 1 | 2020 | 964 | 0.14 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.13 | Why? |
| Multimodal Imaging | 1 | 2018 | 534 | 0.13 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2018 | 724 | 0.13 | Why? |
| Intestinal Mucosa | 1 | 2021 | 1046 | 0.12 | Why? |
| Viral Tropism | 1 | 2021 | 1329 | 0.12 | Why? |
| Membrane Glycoproteins | 1 | 2002 | 2273 | 0.12 | Why? |
| Nasal Mucosa | 1 | 2020 | 1218 | 0.12 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 669 | 0.12 | Why? |
| Mice | 8 | 2019 | 21357 | 0.12 | Why? |
| Nanotechnology | 1 | 2018 | 821 | 0.12 | Why? |
| Acute Kidney Injury | 3 | 2021 | 5762 | 0.12 | Why? |
| Calcium | 1 | 2017 | 708 | 0.12 | Why? |
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1014 | 0.11 | Why? |
| Proportional Hazards Models | 3 | 2021 | 6543 | 0.11 | Why? |
| Extracellular Vesicles | 1 | 2018 | 607 | 0.11 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.11 | Why? |
| Multiple Myeloma | 1 | 2021 | 1064 | 0.11 | Why? |
| Biopsy | 2 | 2017 | 2811 | 0.11 | Why? |
| HLA Antigens | 1 | 2017 | 830 | 0.11 | Why? |
| Exosomes | 1 | 2017 | 567 | 0.11 | Why? |
| Neoplasms | 2 | 2017 | 17251 | 0.10 | Why? |
| Humans | 44 | 2021 | 930598 | 0.10 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2020 | 2483 | 0.10 | Why? |
| Prognosis | 6 | 2021 | 32490 | 0.10 | Why? |
| Systems Theory | 1 | 2009 | 20 | 0.10 | Why? |
| Diagnostic Tests, Routine | 1 | 2021 | 2643 | 0.10 | Why? |
| Apoptosis | 2 | 2017 | 2335 | 0.09 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.09 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.09 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2020 | 1322 | 0.09 | Why? |
| Lung Neoplasms | 3 | 2017 | 3228 | 0.09 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 7868 | 0.09 | Why? |
| Biomarkers, Tumor | 4 | 2018 | 1314 | 0.09 | Why? |
| Tumor Suppressor Protein p53 | 2 | 2018 | 310 | 0.09 | Why? |
| Lung | 3 | 2021 | 31049 | 0.09 | Why? |
| Cardiomyopathies | 1 | 2017 | 997 | 0.09 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.09 | Why? |
| Reproducibility of Results | 3 | 2020 | 11304 | 0.08 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Xenograft Model Antitumor Assays | 2 | 2018 | 274 | 0.08 | Why? |
| Predictive Value of Tests | 3 | 2020 | 9537 | 0.08 | Why? |
| Immunohistochemistry | 4 | 2021 | 2275 | 0.08 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Male | 26 | 2021 | 367725 | 0.08 | Why? |
| Aged | 17 | 2021 | 215776 | 0.08 | Why? |
| Nasopharynx | 3 | 2021 | 10224 | 0.08 | Why? |
| Glutathione S-Transferase pi | 1 | 2005 | 10 | 0.08 | Why? |
| Liver | 1 | 2021 | 4007 | 0.08 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.08 | Why? |
| Cell Culture Techniques | 1 | 2011 | 704 | 0.08 | Why? |
| Gastrointestinal Diseases | 1 | 2021 | 2580 | 0.07 | Why? |
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 116 | 0.07 | Why? |
| Myocardium | 1 | 2017 | 2323 | 0.07 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.07 | Why? |
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 343 | 0.07 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.07 | Why? |
| Smoking | 2 | 2010 | 3358 | 0.07 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.07 | Why? |
| Sarcoma, Clear Cell | 1 | 2003 | 2 | 0.07 | Why? |
| Animals | 9 | 2021 | 78931 | 0.07 | Why? |
| Carcinoma, Renal Cell | 1 | 2011 | 545 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.07 | Why? |
| Parathyroid Neoplasms | 1 | 2003 | 18 | 0.06 | Why? |
| Drug Resistance, Neoplasm | 2 | 2017 | 447 | 0.06 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.06 | Why? |
| Treatment Failure | 1 | 2009 | 2106 | 0.06 | Why? |
| RNA | 2 | 2021 | 1278 | 0.06 | Why? |
| Kidney Neoplasms | 1 | 2011 | 832 | 0.06 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Female | 19 | 2021 | 380317 | 0.06 | Why? |
| Soft Tissue Neoplasms | 1 | 2003 | 131 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.06 | Why? |
| Brain | 1 | 2019 | 5133 | 0.06 | Why? |
| Disease Models, Animal | 1 | 2019 | 10998 | 0.05 | Why? |
| Molecular Diagnostic Techniques | 1 | 2017 | 4239 | 0.05 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.05 | Why? |
| Laryngectomy | 1 | 2002 | 145 | 0.05 | Why? |
| Adenoma | 1 | 2003 | 215 | 0.05 | Why? |
| Cell Proliferation | 2 | 2018 | 1973 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Blotting, Western | 1 | 2002 | 863 | 0.05 | Why? |
| Carcinoma | 1 | 2003 | 256 | 0.05 | Why? |
| Inflammation Mediators | 2 | 2021 | 2654 | 0.05 | Why? |
| Microscopy, Electron | 1 | 2002 | 830 | 0.05 | Why? |
| Basigin | 1 | 2002 | 276 | 0.05 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.05 | Why? |
| Hospitals, Private | 1 | 2020 | 198 | 0.05 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Hematuria | 1 | 2020 | 284 | 0.05 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.05 | Why? |
| Polymorphism, Genetic | 1 | 2005 | 1074 | 0.04 | Why? |
| cdc25 Phosphatases | 1 | 2017 | 5 | 0.04 | Why? |
| Receptors, Somatomedin | 1 | 2017 | 7 | 0.04 | Why? |
| Receptor, IGF Type 1 | 1 | 2017 | 24 | 0.04 | Why? |
| Mammary Neoplasms, Experimental | 1 | 2017 | 21 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| Mice, Inbred NOD | 1 | 2017 | 134 | 0.04 | Why? |
| Tumor Cells, Cultured | 2 | 2011 | 254 | 0.04 | Why? |
| Ubiquitin-Conjugating Enzymes | 1 | 2017 | 27 | 0.04 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.04 | Why? |
| Genes, Tumor Suppressor | 1 | 2017 | 43 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2010 | 3607 | 0.04 | Why? |
| Mice, SCID | 1 | 2017 | 225 | 0.04 | Why? |
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 78 | 0.04 | Why? |
| S-Adenosylmethionine | 1 | 2017 | 137 | 0.04 | Why? |
| Binding, Competitive | 1 | 2017 | 264 | 0.04 | Why? |
| Benchmarking | 1 | 2021 | 627 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Proteinuria | 1 | 2020 | 474 | 0.04 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.04 | Why? |
| Cell Transformation, Neoplastic | 1 | 2018 | 191 | 0.04 | Why? |
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 127 | 0.04 | Why? |
| Calcium Signaling | 1 | 2017 | 133 | 0.04 | Why? |
| Pregnancy Complications, Neoplastic | 1 | 2017 | 79 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.04 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.04 | Why? |
| Metabolic Networks and Pathways | 1 | 2018 | 285 | 0.04 | Why? |
| Risk Adjustment | 1 | 2020 | 730 | 0.04 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2017 | 249 | 0.04 | Why? |
| Cytoplasm | 1 | 2017 | 304 | 0.04 | Why? |
| Everolimus | 1 | 2017 | 215 | 0.04 | Why? |
| Ubiquitin | 1 | 2017 | 243 | 0.04 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.04 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 347 | 0.04 | Why? |
| Gene Deletion | 1 | 2017 | 430 | 0.04 | Why? |
| Hospitals, Urban | 1 | 2020 | 950 | 0.04 | Why? |
| Laryngeal Neoplasms | 2 | 2010 | 202 | 0.03 | Why? |
| Gene Expression | 2 | 2018 | 3332 | 0.03 | Why? |
| Protein Stability | 1 | 2017 | 756 | 0.03 | Why? |
| Cell Nucleus | 1 | 2017 | 399 | 0.03 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.03 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.03 | Why? |
| Endoplasmic Reticulum | 1 | 2017 | 430 | 0.03 | Why? |
| Morbidity | 1 | 2020 | 1426 | 0.03 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.03 | Why? |
| Carcinoma, Squamous Cell | 1 | 2002 | 902 | 0.03 | Why? |
| Leukocytes | 1 | 2020 | 1046 | 0.03 | Why? |
| Proteolysis | 1 | 2017 | 751 | 0.03 | Why? |
| New York | 1 | 2021 | 2488 | 0.03 | Why? |
| HeLa Cells | 1 | 2017 | 1303 | 0.03 | Why? |
| Adult | 10 | 2021 | 244371 | 0.03 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.03 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Photochemotherapy | 1 | 2017 | 297 | 0.03 | Why? |
| Melanoma | 1 | 2003 | 1229 | 0.03 | Why? |
| Cell Growth Processes | 1 | 2011 | 12 | 0.03 | Why? |
| Sepharose | 1 | 2011 | 12 | 0.03 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.03 | Why? |
| Metabolomics | 1 | 2017 | 921 | 0.03 | Why? |
| Hospitals | 2 | 2020 | 11793 | 0.03 | Why? |
| Host-Pathogen Interactions | 2 | 2021 | 11041 | 0.03 | Why? |
| Coculture Techniques | 1 | 2011 | 258 | 0.03 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.03 | Why? |
| Small Molecule Libraries | 1 | 2018 | 1060 | 0.03 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.02 | Why? |
| Head and Neck Neoplasms | 1 | 2002 | 1568 | 0.02 | Why? |
| Cells, Cultured | 1 | 2021 | 5835 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2018 | 2290 | 0.02 | Why? |
| Oropharyngeal Neoplasms | 1 | 2010 | 138 | 0.02 | Why? |
| Validation Studies as Topic | 1 | 2009 | 121 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Hemorrhage | 1 | 2020 | 3013 | 0.02 | Why? |
| Prostate-Specific Antigen | 1 | 2009 | 213 | 0.02 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Electronic Health Records | 1 | 2020 | 3492 | 0.02 | Why? |
| Cause of Death | 1 | 2021 | 4823 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Isoleucine | 1 | 2005 | 19 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Histocytological Preparation Techniques | 1 | 2003 | 17 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.02 | Why? |
| Renal Dialysis | 1 | 2020 | 4358 | 0.02 | Why? |
| Pharyngeal Neoplasms | 1 | 2002 | 17 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.02 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.02 | Why? |
| Ki-67 Antigen | 1 | 2003 | 139 | 0.02 | Why? |
| African Americans | 1 | 2018 | 3363 | 0.02 | Why? |
| Phylogeny | 1 | 2021 | 13341 | 0.01 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Cell Cycle Proteins | 1 | 2003 | 297 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| Immunoenzyme Techniques | 1 | 2003 | 448 | 0.01 | Why? |
| Protein Binding | 1 | 2017 | 11430 | 0.01 | Why? |
| Mice, Inbred BALB C | 1 | 2011 | 5814 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Drug Repositioning | 1 | 2018 | 5683 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Immunophenotyping | 1 | 2002 | 1290 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Italy | 1 | 2021 | 38444 | 0.01 | Why? |
| Transcription, Genetic | 1 | 2002 | 1326 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Neoplasm Recurrence, Local | 1 | 2003 | 1063 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Odds Ratio | 1 | 2005 | 5861 | 0.01 | Why? |
| Alcohol Drinking | 1 | 2005 | 1663 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2002 | 5440 | 0.01 | Why? |
| Patient Selection | 1 | 2005 | 4560 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Survival Analysis | 1 | 2002 | 7592 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2003 | 7220 | 0.01 | Why? |
| Artificial Intelligence | 1 | 2003 | 3543 | 0.01 | Why? |